Genprex faces Nasdaq delisting for both equity and bid price non-compliance; hearing requested

Genprex, Inc.

Stockholders' equity of $1.39M as of June 30, 2025, below Nasdaq's $2.5M minimum requirement.
Also non-compliant with $1.00 bid price rule; previous delisting determination from Aug 12, 2025.
Company requested a hearing on Aug 19, 2025, which stays delisting pending Panel decision.
No assurance that Panel will grant continued listing or extension.

item 3.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.